Literature DB >> 22446981

Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients.

Hui Zhou1, Yan Gao, Xiao-Liang Cheng, Zhong-Dong Li.   

Abstract

To set up a population pharmacokinetic (PPK) model of cyclosporine A (CsA) in Chinese allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients to provide reference for individualized medication in clinical practice. 281 trough plasma concentrations of CsA and covariates such as demographics, clinical laboratory values and coadministration were retrospectively collected from 73 allo-HSCT patients. Population modeling was performed using general model of NONMEM expressed by differential equation. Hematocrit (HCT), plasma albumin (ALB) level, and coadministration of itraconazole (ITR) were found to significantly affect the clearance of CsA (CL, L/h). The final model formula was: CL = 28.2 × [1 - 0.0263 × (HCT - 26.62)] × [1 - 0.0289 × (ALB - 37.63)] × [1 - 0.146 × ITR] (L/h); V = 1,080 (L); K (a) = 1.28 (h⁻¹); F = 0.711. The interindividual variabilities for CL, V and F were 21.4, 41.5 and 6.07 %, respectively. The residual error was 0.00422 mg/L. The PPK model was validated to be effective and stable by bootstrap method. Clinical applications showed there was a good linear correlation between the predicted concentrations and the observed (y = 1.0095x + 0.0082, r = 0.9309, p < 0.0001). The PPK final model of CsA in Chinese allo-HSCT patients can be established using the NONMEM program which can be applied in clinical allo-HSCT practice when characteristics of patients fit in with those of subpopulation in the study.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22446981     DOI: 10.1007/s13318-012-0087-8

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  23 in total

1.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

Review 2.  Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.

Authors:  María del Mar Fernández De Gatta; Dolores Santos-Buelga; Alfonso Domínguez-Gil; María José García
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1985-04

4.  Population pharmacokinetics of cyclosporine in clinical renal transplant patients.

Authors:  Ke-Hua Wu; Yi-Min Cui; Jin-Feng Guo; Ying Zhou; Suo-Di Zhai; Fu-De Cui; Wei Lu
Journal:  Drug Metab Dispos       Date:  2005-06-02       Impact factor: 3.922

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

6.  Ciclosporin kinetics in children after stem cell transplantation.

Authors:  A J Willemze; S C Cremers; R C Schoemaker; A C Lankester; J den Hartigh; J Burggraaf; J M Vossen
Journal:  Br J Clin Pharmacol       Date:  2008-04-30       Impact factor: 4.335

7.  Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation.

Authors:  Pamala A Jacobson; Juki Ng; Kathleen G E Green; John Rogosheske; Richard Brundage
Journal:  Biol Blood Marrow Transplant       Date:  2003-05       Impact factor: 5.742

8.  Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve.

Authors:  Elias David-Neto; Lilian M P Araujo; Zita M L Brito; Cristiane F Alves; Francine C Lemos; Elisa M Yagyu; William C Nahas; Luiz E Ianhez
Journal:  Am J Transplant       Date:  2002-07       Impact factor: 8.086

Review 9.  Evolution of the therapeutic drug monitoring of cyclosporine.

Authors:  F Citterio
Journal:  Transplant Proc       Date:  2004-03       Impact factor: 1.066

10.  A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients.

Authors:  Pål Falck; Karsten Midtvedt; Thanh Trúc Vân Lê; Live Storehagen; Hallvard Holdaas; Anders Hartmann; Anders Asberg
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more
  8 in total

1.  Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients.

Authors:  Ling Xue; Wen-Juan Zhang; Ji-Xin Tian; Lin-Na Liu; Hai-Hong Yan; Wen-Wen Zhang; Xiao-Liang Ding; Jing-Jing Zhang; Li-Yan Miao
Journal:  Pharm Res       Date:  2019-12-23       Impact factor: 4.200

2.  Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration.

Authors:  Shao-qing Ni; Wei Zhao; Jue Wang; Su Zeng; Shu-qing Chen; Evelyne Jacqz-Aigrain; Zheng-yan Zhao
Journal:  Acta Pharmacol Sin       Date:  2013-04-29       Impact factor: 6.150

3.  Effect of posaconazole on the concentration of intravenous and oral cyclosporine in patients undergoing hematopoietic stem cell transplantation.

Authors:  Li-E Zhu; Hui-Ping Huang; Yi-Peng Cai; Yan Wang; Bao-Hua Xu; Mao-Bai Liu; Xue-Mei Wu
Journal:  Eur J Clin Pharmacol       Date:  2022-08-31       Impact factor: 3.064

Review 4.  Population pharmacokinetics of cyclosporine in transplant recipients.

Authors:  Kelong Han; Venkateswaran C Pillai; Raman Venkataramanan
Journal:  AAPS J       Date:  2013-06-18       Impact factor: 4.009

5.  Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients.

Authors:  Jean-Baptiste Woillard; Vincent Lebreton; Michael Neely; Pascal Turlure; Stéphane Girault; Jean Debord; Pierre Marquet; Franck Saint-Marcoux
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

6.  The first study in pediatric: Population pharmacokinetics of sirolimus and its application in Chinese children with immune cytopenia.

Authors:  Xiaoling Cheng; Yiming Zhao; Hao Gu; Libo Zhao; Yannan Zang; Xiaoling Wang; Runhui Wu
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

7.  Population Pharmacokinetics of Cyclosporine in Chinese Pediatric Patients With Acquired Aplastic Anemia.

Authors:  Xuan Gao; Zhu-Li Bian; Xiao-Hong Qiao; Xiao-Wen Qian; Jun Li; Guo-Mei Shen; Hui Miao; Yi Yu; Jian-Hua Meng; Xiao-Hua Zhu; Jun-Ye Jiang; Jun Le; Ling Yu; Hong-Sheng Wang; Xiao-Wen Zhai
Journal:  Front Pharmacol       Date:  2022-07-26       Impact factor: 5.988

8.  Analysis of the variable factors affecting changes in the blood concentration of cyclosporine before and after transfusion of red blood cell concentrate.

Authors:  Masashi Uchida; Natsumi Hanada; Shingo Yamazaki; Hirokazu Takatsuka; Chiaki Imai; Akari Utsumi; Yuki Shiko; Yohei Kawasaki; Takaaki Suzuki; Itsuko Ishii
Journal:  J Pharm Health Care Sci       Date:  2022-02-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.